Sentence examples for marker of target from inspiring English sources

Arterial stiffness has been shown to be an independent predictor of cardiovascular mortality and an early marker of target organ damage by cardiovascular disease.

Furthermore, these trogocytosed-HER2+ immune effector cells show significantly higher levels of CD107a expression, a marker of target cancer cell cytotoxicity, compared to non-trogocytosed-HER2 immune effector cells.

A blunted SND-ratio has also been identified as an independent risk marker of target organ damage and cardiovascular disease in patients with long duration of diabetes [ 31, 32].

Thus, accumulating indirect evidence suggests that cortical hyperactivity may play an important role in the pathophysiology of AD, making chronic EEG recordings a promising marker of target engagement and efficacy for new drugs for AD.

Nevertheless, this result was demonstrated by previous authors who showed that RI is a marker of target organ damage in essential hypertension [ 30, 32, 34, 36, 37] as left ventricular hypertrophy, carotid and coronary atherosclerosis.

The secondary objectives were to characterize the pharmacokinetics of ixazomib in plasma and urine, to characterize the pharmacodynamic effects of IV ixazomib on 20S proteasome inhibition in whole blood as a marker of target inhibition, and to assess preliminary disease response.

We next investigated the subsequent cellular localization of NP1 following internalization, by colocalizing NP1 fluorescence with that of fluorescent markers of target organelles.

It is therefore interesting that some of the observed drug-related adverse events may act as surrogate markers of target inhibition.

Thus, the FDG-PET findings in this study did not align well with the dose-dependency observed for effects on pharmacodynamic markers of target engagement.

Markers of target engagement, blood pressure and sVEGFR2, and end points of safety and efficacy were examined to investigate the range of plasma pazopanib concentrations that could optimise benefit to patients with RCC.

The lack of correlation between markers of target engagement and clinical outcome measures is still an unsolved issue in AD trials, which mirrors the knowledge gap of the disease pathogenesis.